Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
243 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01875705 | A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 40 | Genentech, Inc.INDUSTRY | 2 | Apr 6, 2018 | clinicaltrials |
| NCT00097487 | A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane | completed | — | 1,000 | Genentech, Inc.INDUSTRY | 0 | Mar 2, 2018 | clinicaltrials |
| NCT01995188 | A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer | completed | Phase 1 | 41 | Genentech, Inc.INDUSTRY | 1 | Oct 4, 2017 | clinicaltrials |
| NCT01991210 | A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) | terminated | Phase 2 | 95 | Genentech, Inc.INDUSTRY | 7 | Aug 21, 2017 | clinicaltrials |
| NCT00434642 | A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma(OCEANS) | completed | Phase 3 | 484 | Genentech, Inc.INDUSTRY | 0 | Aug 9, 2017 | clinicaltrials |
| NCT01604252 | An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC) | terminated | — | 503 | Genentech, Inc.INDUSTRY | 2 | Jul 28, 2017 | clinicaltrials |
| NCT00434252 | A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma(BEAM) | completed | Phase 2 | 214 | Genentech, Inc.INDUSTRY | 0 | Jul 18, 2017 | clinicaltrials |
| NCT00726661 | An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)(VIRGO) | completed | — | 1,287 | Genentech, Inc.INDUSTRY | 0 | Jul 11, 2017 | clinicaltrials |
| NCT00968981 | A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists | completed | Phase 1 | 67 | Genentech, Inc.INDUSTRY | 0 | Jul 11, 2017 | clinicaltrials |
| NCT00496132 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 16 | Genentech, Inc.INDUSTRY | 0 | Jul 2, 2017 | clinicaltrials |
| NCT00977067 | A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies | terminated | Phase 1 | 40 | Genentech, Inc.INDUSTRY | 0 | Jun 21, 2017 | clinicaltrials |
| NCT00473590 | A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)(AMBER) | completed | Phase 2 | 102 | Genentech, Inc.INDUSTRY | 0 | Jun 14, 2017 | clinicaltrials |
| NCT00548548 | A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer(AVAGAST) | completed | Phase 3 | 774 | Genentech, Inc.INDUSTRY | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00636610 | A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer | completed | Phase 2 | 199 | Genentech, Inc.INDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT00739661 | A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission | completed | Phase 2 | 104 | Genentech, Inc.INDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT01363947 | Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer | completed | Phase 1 | 87 | Genentech, Inc.INDUSTRY | 2 | Jun 7, 2017 | clinicaltrials |
| NCT00517049 | A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g) | completed | Phase 2 | 49 | Genentech, Inc.INDUSTRY | 0 | Jun 6, 2017 | clinicaltrials |
| NCT01418222 | FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 194 | Genentech, Inc.INDUSTRY | 1 | May 30, 2017 | clinicaltrials |
| NCT01586195 | Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E | terminated | Phase 2 | 31 | Genentech, Inc.INDUSTRY | 1 | May 25, 2017 | clinicaltrials |
| NCT00480831 | A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g) | completed | Phase 2 | 128 | Genentech, Inc.INDUSTRY | 0 | May 18, 2017 | clinicaltrials |
| NCT00954642 | A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 24 | Genentech, Inc.INDUSTRY | 0 | May 17, 2017 | clinicaltrials |
| NCT00097019 | A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed | completed | Phase 2 | 53 | Genentech, Inc.INDUSTRY | 0 | May 16, 2017 | clinicaltrials |
| NCT00345163 | A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)(BRAIN) | completed | Phase 2 | 167 | Genentech, Inc.INDUSTRY | 0 | May 16, 2017 | clinicaltrials |
| NCT00477425 | A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab | withdrawn | — | 0 | Genentech, Inc.INDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT00719472 | A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)(RATE) | completed | Phase 3 | 451 | Genentech, Inc.INDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT01493843 | Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | completed | Phase 2 | 501 | Genentech, Inc.INDUSTRY | 16 | Apr 25, 2017 | clinicaltrials |
| NCT01740336 | A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 183 | Genentech, Inc.INDUSTRY | 8 | Apr 24, 2017 | clinicaltrials |
| NCT01414205 | A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE) | completed | Phase 2 | 80 | Genentech, Inc.INDUSTRY | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01868893 | An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia | completed | Phase 2 | 20 | Genentech, Inc.INDUSTRY | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01359696 | A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 40 | Genentech, Inc.INDUSTRY | 2 | Apr 12, 2017 | clinicaltrials |
| NCT00453362 | A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib | completed | Phase 1 / Phase 2 | 88 | Genentech, Inc.INDUSTRY | 0 | Mar 31, 2017 | clinicaltrials |
| NCT00679211 | A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer | completed | Phase 2 | 110 | Genentech, Inc.INDUSTRY | 0 | Mar 31, 2017 | clinicaltrials |
| NCT00854308 | A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib) | completed | Phase 2 | 137 | Genentech, Inc.INDUSTRY | 0 | Mar 31, 2017 | clinicaltrials |
| NCT00097565 | An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma | completed | — | 2,740 | Genentech, Inc.INDUSTRY | 0 | Mar 23, 2017 | clinicaltrials |
| NCT00058552 | A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer | completed | Phase 2 | 129 | Genentech, Inc.INDUSTRY | 0 | Mar 8, 2017 | clinicaltrials |
| NCT01120561 | A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer | no longer available | — | — | Genentech, Inc.INDUSTRY | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02048709 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors | completed | Phase 1 | 22 | Genentech, Inc.INDUSTRY | 1 | Feb 6, 2017 | clinicaltrials |
| NCT01300247 | A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON) | completed | Phase 1 | 41 | Genentech, Inc.INDUSTRY | 1 | Feb 2, 2017 | clinicaltrials |
| NCT01186991 | Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer | completed | Phase 2 | 185 | Genentech, Inc.INDUSTRY | 6 | Jan 20, 2017 | clinicaltrials |
| NCT01469793 | A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer | completed | Phase 1 | 71 | Genentech, Inc.INDUSTRY | 2 | Jan 10, 2017 | clinicaltrials |
| NCT00996892 | Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 178 | Genentech, Inc.INDUSTRY | 1 | Dec 30, 2016 | clinicaltrials |
| NCT00854126 | A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 38 | Genentech, Inc.INDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials